CN102796820B - Hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use - Google Patents
Hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use Download PDFInfo
- Publication number
- CN102796820B CN102796820B CN2012102997487A CN201210299748A CN102796820B CN 102796820 B CN102796820 B CN 102796820B CN 2012102997487 A CN2012102997487 A CN 2012102997487A CN 201210299748 A CN201210299748 A CN 201210299748A CN 102796820 B CN102796820 B CN 102796820B
- Authority
- CN
- China
- Prior art keywords
- hepatocellular carcinoma
- klotho gene
- nucleotide polymorphism
- klotho
- polymorphism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108050004036 Klotho Proteins 0.000 title claims abstract description 36
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 31
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 27
- 239000002773 nucleotide Substances 0.000 title claims abstract description 21
- 238000010276 construction Methods 0.000 title abstract description 5
- 102220164833 rs648202 Human genes 0.000 claims abstract description 18
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 17
- 238000001514 detection method Methods 0.000 claims abstract description 3
- 108020004414 DNA Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 abstract description 7
- 102000015834 Klotho Human genes 0.000 abstract description 7
- 230000014509 gene expression Effects 0.000 abstract description 6
- 230000002068 genetic effect Effects 0.000 abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 238000009510 drug design Methods 0.000 abstract description 3
- 108010012003 GGCC-specific type II deoxyribonucleases Proteins 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000007877 drug screening Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 101001139093 Homo sapiens Klotho Proteins 0.000 abstract 1
- 238000011895 specific detection Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 6
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003550 marker Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000032683 aging Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004057 allelic distribution Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明提供了一种原发性肝细胞性肝癌相关的klotho基因单核苷酸多态性其构建方法及其应用,属于基因工程生物技术领域。The invention provides a construction method and application of a klotho gene single nucleotide polymorphism related to primary hepatocellular carcinoma, belonging to the field of genetic engineering biotechnology.
背景技术Background technique
原发性肝细胞性肝癌(简称肝癌,HCC)是世界范围内最常见的恶性肿瘤之一,2007年12月美国癌症学会(ACS)发布的数据显示:肝癌年增66.7万例,死亡59.8万例,其中约50%的新患病例和死亡病例在中国,即肝癌对我国人民的健康威胁更大,已成为我国第二位肿瘤杀手,不仅使患者痛苦不堪,生存率低,而且给家庭、社会带来严重的经济和心理负担。Primary hepatocellular carcinoma (liver cancer, HCC) is one of the most common malignant tumors in the world. In December 2007, the data released by the American Cancer Society (ACS) showed that there were 667,000 cases of liver cancer and 598,000 deaths per year. Among them, about 50% of new cases and deaths are in China, that is, liver cancer poses a greater threat to the health of our people and has become the second cancer killer in our country. , society brings serious economic and psychological burden.
单核苷酸多态性(SNP)是指基因组水平上由单个核苷酸的变异引起的多态性。它是人类可遗传的变异中最常见的一种,占所有已知多态性的90%以上。SNP作为稳定遗传的早期突变,与疾病密切相关。当一种SNP在患者中的出现频率明显高于非患者,提示该SNP与此疾病相关,通过分析研究两者的单倍型和连锁不平衡性,可将基因组中任何未知的致病基因定位。SNP在致病基因定位中发挥的作用主要包括:一是在寻找致病SNP,这种SNP的出现可导致基因在表达量和(或)蛋白表达产物结构的变化,从而导致某种疾病的发生或使得个体对某种疾病易感;二是SNP作为一种遗传标记,与疾病或者表型连锁。Single nucleotide polymorphism (SNP) refers to the polymorphism caused by the variation of a single nucleotide at the genome level. It is the most common type of heritable variation in humans, accounting for more than 90% of all known polymorphisms. SNPs, as stable genetic early mutations, are closely related to diseases. When the frequency of a SNP in patients is significantly higher than that in non-patients, it is suggested that the SNP is related to the disease. By analyzing the haplotype and linkage disequilibrium of the two, any unknown pathogenic gene in the genome can be located . The role of SNP in the localization of disease-causing genes mainly includes: one is to look for disease-causing SNP, the appearance of this SNP can lead to changes in gene expression and (or) protein expression product structure, thereby leading to the occurrence of certain diseases Or make an individual susceptible to a certain disease; the second is that SNP, as a genetic marker, is linked to a disease or phenotype.
Klotho是1997年发现与衰老相关的基因,位于人类染色体13q12,长度约为50kb,由5个外显子和4个内含子组成。Klotho基因在小鼠中的表达缺失导致其出现类似于人类衰老的各种表型,如动脉硬化、骨质疏松、肺气肿、寿命缩短、皮肤萎缩、不育症、运动失调等。近年来,越来越多的研究发现klotho基因可以调节IGF、Wnt、TGF-βl、FGF等信号通路,参与氧化应激过程,并且与机体的免疫缺陷有关,在恶性肿瘤的发生发展过程中发挥类似抑癌基因的重要作用。因此可以利用klotho来作为肿瘤发生、分级的标志物以及作为靶点用于抗肿瘤的治疗。Klotho is an aging-related gene discovered in 1997. It is located on human chromosome 13q12 and is about 50kb in length, consisting of 5 exons and 4 introns. Loss of Klotho gene expression in mice leads to various phenotypes similar to human aging, such as arteriosclerosis, osteoporosis, emphysema, shortened lifespan, skin atrophy, infertility, movement disorders, etc. In recent years, more and more studies have found that klotho gene can regulate IGF, Wnt, TGF-βl, FGF and other signaling pathways, participate in the process of oxidative stress, and is related to the body's immune deficiency, and plays a role in the occurrence and development of malignant tumors. Similar to the important role of tumor suppressor genes. Therefore, klotho can be used as a marker for tumorigenesis and grading and as a target for anti-tumor therapy.
对现有技术的国内外文献和专利进行检索,至今未见任何klotho基因多态性与肝细胞肝癌易感性关系的相关报道。Searching domestic and foreign literature and patents of the prior art has not found any relevant reports on the relationship between klotho gene polymorphisms and susceptibility to hepatocellular carcinoma.
发明内容Contents of the invention
本发明的目的在于填补现有技术的空白,提供一种原发性肝细胞性肝癌相关的klotho基因单核苷酸多态性其构建方法及其应用。The purpose of the present invention is to fill up the gap in the prior art, and provide a method for constructing the single nucleotide polymorphism of klotho gene related to primary hepatocellular carcinoma and its application.
本发明提供了一种检测原发性肝细胞性肝癌相关的klotho基因单核苷酸多态性的方法,采用PCR-RFLP方法,包括以下步骤:The present invention provides a method for detecting single nucleotide polymorphism of klotho gene related to primary hepatocellular carcinoma, which adopts PCR-RFLP method, comprising the following steps:
(1)以包含klotho基因的待测人全基因组DNA为模板,PCR扩增得到klotho基因外显子4区的包含rs648202单核苷酸多态的DNA序列,即SEQ ID No.1中第2190位至第2352位所示序列,(1) Using the whole genome DNA of the human being to be tested comprising the klotho gene as a template, PCR amplifies the DNA sequence comprising the rs648202 single nucleotide polymorphism in the
其中,PCR引物序列如下:Wherein, the PCR primer sequence is as follows:
上游引物为F:5’-ATAGCCTTGCAGGCTGATTG-3’The upstream primer is F: 5'-ATAGCCTTGCAGGCTGATTG-3'
下游引物为R:5’-TTCTTTGGTTCAGCCAGTCC-3’The downstream primer is R: 5'-TTCTTTGGTTCAGCCAGTCC-3'
(2)对PCR扩增产物经限制性内切酶Hae III进行酶切后通过琼脂糖凝胶电泳进行rs648202单核苷酸多态分型,CC基因型酶切后的DNA片段长度仍为163bp;CT基因型酶切后产生163bp、100bp、63bp三种长度的DNA片段;TT基因型酶切后产生100bp、63bp二种长度的DNA片段。(2) After digesting the PCR amplification product with restriction endonuclease Hae III, the rs648202 single nucleotide polymorphism was typed by agarose gel electrophoresis, and the length of the DNA fragment after digestion of the CC genotype was still 163bp ; DNA fragments of three lengths: 163bp, 100bp, and 63bp will be produced after enzyme digestion for the CT genotype; DNA fragments of two lengths: 100bp and 63bp will be produced after enzyme digestion for the TT genotype.
本发明还提供了一种分离核酸,具有SEQ ID No.1中第2190位至第2352位所示序列,且在SEQ ID No.1中的第2255位的碱基为T。The present invention also provides an isolated nucleic acid, which has the sequence shown from No. 2190 to No. 2352 in SEQ ID No. 1, and the base at No. 2255 in SEQ ID No. 1 is T.
本发明还提供了一种检测原发性肝细胞性肝癌相关的klotho基因单核苷酸多态性的特异性引物,上游引物为F:5’-ATAGCCTTGCAGGCTGATTG-3’,下游引物为R:5’-TTCTTTGGTTCAGCCAGTCC-3’。The present invention also provides a specific primer for detecting the single nucleotide polymorphism of klotho gene related to primary hepatocellular carcinoma, the upstream primer is F: 5'-ATAGCCTTGCAGGCTGATTG-3', and the downstream primer is R: 5 '-TTCTTTGGTTCAGCCAGTCC-3'.
本发明还提供了一种原发性肝细胞肝癌易感性的诊断试剂盒,它包括:The present invention also provides a diagnostic kit for the susceptibility of primary hepatocellular carcinoma, which comprises:
(1)特异性扩增klotho基因单核苷酸多态性rs648202的引物,其中,上游引物为F:5’-ATAGCCTTGCAGGCTGATTG-3’,下游引物为R:5’-TTCTTTGGTTCAGCCAGTCC-3’;(1) Primers for specifically amplifying the single nucleotide polymorphism rs648202 of the klotho gene, wherein the upstream primer is F: 5'-ATAGCCTTGCAGGCTGATTG-3', and the downstream primer is R: 5'-TTCTTTGGTTCAGCCAGTCC-3';
(2)检测扩增产物与正常的klotho基因相比是否存在变化所需的试剂。(2) Reagents needed to detect whether there is a change in the amplified product compared with the normal klotho gene.
利用本发明所提供的与原发性肝细胞肝癌相关的多态性位点的核酸序列,可构建对原发性肝细胞肝癌易感人群进行遗传筛选的试剂盒,将其作为药物设计的靶点,找出具有调节klotho基因表达的活性分子,从而促进新的抗肿瘤药物的发现。Utilizing the nucleic acid sequence of the polymorphic site associated with primary hepatocellular carcinoma provided by the present invention, a kit for genetic screening of primary hepatocellular carcinoma susceptible populations can be constructed and used as a target for drug design. Points to find out the active molecules that regulate the expression of klotho gene, thereby promoting the discovery of new anti-tumor drugs.
本发明具有如下技术效果:The present invention has following technical effect:
(1)本发明所建立的方法可以简便快捷地检测位于人类染色体13q12区域klotho基因外显子4区单核苷酸多态性位点rs648202的基因型,通过检测T等位基因的有无判断个体是否对原发性肝细胞肝癌具有易感性,从而有利于原发性肝细胞肝癌易感人群的筛查和原发性肝细胞肝癌的预防;(1) The method established by the present invention can easily and quickly detect the genotype of the single nucleotide polymorphism site rs648202 located in the
(2)利用rs648202的T等位位点作为药物设计靶点进行药物的筛选,筛选出能够调节klotho基因表达水平的活性分子,促进新的抗肿瘤药物的发现;(2) Use the T allele of rs648202 as the drug design target for drug screening, screen out active molecules that can regulate the expression level of klotho gene, and promote the discovery of new anti-tumor drugs;
(3)利用本发明提供的引物序列和Hae III核酸内切酶可以简便、高效、特异地检测出rs648202多态;(3) The rs648202 polymorphism can be detected easily, efficiently and specifically by using the primer sequences and Hae III endonuclease provided by the present invention;
(4)利用本发明提供的原发性肝细胞性肝癌相关的klotho基因单核苷酸多态性,构建对原发性肝细胞肝癌进行遗传性诊断的试剂盒;(4) using the single nucleotide polymorphism of klotho gene related to primary hepatocellular carcinoma provided by the present invention to construct a kit for genetic diagnosis of primary hepatocellular carcinoma;
(5)由于klotho参与了恶性增殖、凋亡、侵袭与转移等细胞活动相关的病理过程,因此本发明对今后深入探讨klotho与其他疾病的关系提供了经验和应用基础。(5) Since klotho participates in pathological processes related to cell activities such as malignant proliferation, apoptosis, invasion and metastasis, the present invention provides experience and application basis for in-depth exploration of the relationship between klotho and other diseases in the future.
附图说明Description of drawings
图l为使用特异性引物对klotho基因外显子4区进行PCR扩增、Hae III酶切后的琼脂糖凝胶电泳图。其中M:DNA分子量标准;l:CT基因型;2:CC基因型;3:TT基因型;4:空白对照。Figure 1 is the agarose gel electrophoresis image after PCR amplification of the
具体实施方式Detailed ways
以下结合具体实施例来进一步说明本发明。需注意的是,以下实施例只用于说明本发明,而不用于限制本发明的范围。The present invention will be further described below in conjunction with specific examples. It should be noted that the following examples are only used to illustrate the present invention, but not to limit the scope of the present invention.
实施例1Example 1
(1)收集血液样本及DNA提取(1) Collection of blood samples and DNA extraction
从南京医科大学第二附属医院采集到散发性的原发性肝细胞肝癌患者样本212例,所有患者均经组织病理学确诊,其中男150例,女62例。患者的平均年龄是62岁;对照组288例,平均年龄是61岁。病例组和对照组的年龄、性别组成无显著性差异(P>0.05)。以上结果表明两组在年龄、性别方面均衡可比。所有研究对象均签署知情同意书。A total of 212 patients with sporadic primary hepatocellular carcinoma were collected from the Second Affiliated Hospital of Nanjing Medical University. All patients were confirmed by histopathology, including 150 males and 62 females. The average age of the patients was 62 years old; the control group 288 cases, the average age was 61 years old. There was no significant difference in age and sex composition between the case group and the control group (P>0.05). The above results indicated that the two groups were balanced and comparable in terms of age and gender. All research subjects signed the informed consent.
使用常规方法从上述收集到的血液样本中分离出白细胞,并采用经典酚-氯仿法抽提白细胞基因组DNA后,将样品统一稀释到0.1μg/μl,作为DNA模板,其余的DNA放置于-20℃保存。White blood cells were isolated from the blood samples collected above using conventional methods, and the genomic DNA of white blood cells was extracted by the classic phenol -chloroform method, and the samples were uniformly diluted to 0.1 μg/μl as DNA templates, and the remaining DNA was placed at -20 Store at ℃.
(2)设计并合成核苷酸引物,引物序列如下所示,(2) Design and synthesize nucleotide primers, the primer sequences are as follows,
上游引物为F:5’-ATAGCCTTGCAGGCTGATTG-3’,The upstream primer is F: 5'-ATAGCCTTGCAGGCTGATTG-3',
下游引物为R:5’-TTCTTTGGTTCAGCCAGTCC-3’。The downstream primer is R: 5'-TTCTTTGGTTCAGCCAGTCC-3'.
进行聚合酶链反应(PCR)Perform polymerase chain reaction (PCR)
进行PCR反应体系:总量为20μlCarry out PCR reaction system: the total amount is 20 μl
PCR扩增仪中设置反应条件: Set the reaction conditions in the PCR instrument:
最终扩增后得到klotho基因外显子4区163bp的包含rs648202单核酸多态的DNA序列,即SEQ ID No.1中第2190位至第2352位所示序列。After the final amplification, a 163bp DNA sequence containing the rs648202 single nucleic acid polymorphism in the
(3)对扩增得到的DNA序列进行单核苷酸多态性分型(3) Perform single nucleotide polymorphism typing on the amplified DNA sequence
对步骤(2)中得到的DNA片段产物,利用限制性核酸内切酶进行限制性片段长度多态性分型。For the DNA fragment products obtained in step (2), restriction endonucleases are used to carry out restriction fragment length polymorphism typing.
具体方法为:5μl PCR扩增产物中加入5U的限制性内切酶HaeIII及相应的10×酶切反应缓冲液1.0μl,加水至10μl,混匀后于37℃下消化6小时。取酶切产物10μl加入1.0μl上样缓冲液,充分混匀,加入3%琼脂糖凝胶的加样孔,以DNA Marker作参照,电泳工作液为1×TBE,使样品由负极向正极移动,恒定电压80V约40分钟后将凝腔板放在紫外透射仪石英玻璃台上进行检测,观察各泳道是否出现荧光带,凝胶图象分析仪分析酶切产物的基因型型别,拍照并记录酶切结果。如图1所示,CC基因型酶切后的DNA片段长度仍为163bp;CT基因型酶切后产生163bp、100bp、63bp三种长度的DNA片段;TT基因型酶切后产生100bp、63bp二种长度的DNA片段。The specific method is: add 5U of restriction endonuclease HaeIII and 1.0 μl of corresponding 10× enzyme digestion reaction buffer to 5 μl of PCR amplification product, add water to 10 μl, mix and digest at 37°C for 6 hours. Take 10 μl of the digested product and add 1.0 μl of loading buffer , mix thoroughly, add to the sample hole of 3% agarose gel, use DNA Marker as a reference, and the electrophoresis working solution is 1×TBE, so that the sample moves from the negative electrode to the positive electrode After about 40 minutes at a constant voltage of 80V, put the coagulation chamber plate on the quartz glass platform of the ultraviolet transilluminator for detection, observe whether there are fluorescent bands in each swimming lane, analyze the genotype of the digested product with a gel image analyzer, take pictures and Record the digestion results. As shown in Figure 1, the length of the DNA fragment after digestion of the CC genotype is still 163bp; DNA fragments of three lengths of 163bp, 100bp, and 63bp are produced after digestion of the CT genotype; DNA fragments of 100bp and 63bp are produced after digestion of the TT genotype DNA fragments of various lengths.
(4)Klotho编码区rs648202单核苷酸多态与原发性肝细胞肝癌遗传易感性之间的相关性分析(4) Correlation analysis between rs648202 single nucleotide polymorphism in Klotho coding region and genetic susceptibility to primary hepatocellular carcinoma
统计方法:采用SPSS11.0软件建立数据库。对病例和对照的klotho基因的等位基因和基因型的频率分布态性及其人口统计变异值、吸烟和饮酒等变量采用χ2检验,以判断所选人群是否存在基因型或等位基因的分布偏差,从而确定其对整体人群的代表性。用单变量logistic回归分析来获得比值比(OR)和95%可信区间(CI),所有OR值经性别和年龄矫正。统计分析用SAS9.0软件,P<0.05为统计学有显著性差异,所有检验均为双侧检验。Statistical method: use SPSS11.0 software to establish the database. The allele and genotype frequency distribution of the klotho gene of the cases and controls, as well as variables such as demographic variation, smoking and drinking, were tested by the χ2 test to determine whether there was a difference in genotype or allele in the selected population. distribution bias to determine its representativeness of the population as a whole. Univariate logistic regression analysis was used to obtain odds ratios (ORs) and 95% confidence intervals (CIs), all OR values adjusted for sex and age. SAS9.0 software was used for statistical analysis, P<0.05 was considered statistically significant difference, and all tests were two-sided tests.
统计结果如下:The statistical results are as follows:
①Klotho基因rs648202位点基因型频率的遗传平衡检验① Genetic balance test of genotype frequency at rs648202 locus of Klotho gene
对Klotho基因rs648202位点基因型频率进行Hardy-Weniberg遗传平衡检验,χ2=2.272,P=0.132,该位点基因频率观察值与期望值之间差异无统计学意义,表明该基因型频率均符合Hardy-Weniberg比例,样本具有群体代表性。The Hardy-Weniberg genetic balance test was performed on the genotype frequency of Klotho gene rs648202 site, χ 2 =2.272, P=0.132, there was no statistically significant difference between the observed value and the expected value of the gene frequency at this site, indicating that the genotype frequency was in line with The Hardy-Weniberg ratio, the sample is representative of the group.
②原发性肝细胞肝癌患者组和健康对照组间的rs648202多态位点基因型及等位位点分布频率如下表1所示:②The genotype and allelic distribution frequency of the rs648202 polymorphic site between the primary hepatocellular carcinoma patient group and the healthy control group are shown in Table 1 below:
表1Klotho基因rs648202多态的基因型和等位基因频率及其与肝癌的关系Table 1 The genotype and allele frequency of Klotho gene rs648202 polymorphism and its relationship with liver cancer
CC、CT和TT基因型频率在病例中分别是57.1%37.7%和5.2%,在对照中分别是68.7%,27.1%和4.2%,基因型的分布差异有显著的统计学意义(P=0.026)。将GA和AA合并与GG比较,两者仍有显著的统计学意义(P=0.007)。Logistic回归分析显示,与携带CC野生型相比,携带变异的CT基因型的个体发生肝癌的危险性显著升高,增加值为59.6%,携带CT+TT突变基因型者的危险性增加60.4%。The CC, CT and TT genotype frequencies were 57.1%, 37.7% and 5.2% in the cases, and 68.7%, 27.1% and 4.2% in the controls, respectively, and the distribution of the genotypes was significantly different (P=0.026 ). Comparing GA and AA with GG, the two are still statistically significant (P=0.007). Logistic regression analysis showed that, compared with CC wild type individuals, the risk of liver cancer in individuals carrying the mutated CT genotype increased significantly, with an increase of 59.6%, and the risk of individuals carrying the CT+TT mutation genotype increased by 60.4% .
这些结果提示,klotho基因外显子4区rs648202是对原发性肝细胞肝癌易感的一个标志性位点。当该位点携带T等位基因即该位点的基因型为T/T或C/T时,其个体发生肝癌的危险性明显高于基因型为C/C的个体,表明C/T或T/T基因型的个体对原发性肝细胞肝癌易感,而C/C基因型的个体对原发性肝细胞肝癌较为不易感。These results suggest that rs648202 in
Organization Applicant Organization Applicant
---------------------- ----------------------
Street : Street :
City : City :
State : State :
Country : Country :
PostalCode : PostalCode :
PhoneNumber : PhoneNumber :
FaxNumber : FaxNumber :
EmailAddress : EmailAddress :
<110> OrganizationName : 南京医科大学第二附属医院 <110> OrganizationName : The Second Affiliated Hospital of Nanjing Medical University
the
Individual Applicant Individual Applicant
-------------------- --------------------
Street : Street :
City : City :
State : State :
Country : Country :
PostalCode : PostalCode :
PhoneNumber : PhoneNumber :
FaxNumber : FaxNumber :
EmailAddress : EmailAddress :
<110> LastName : 黄 <110> LastName : Huang
<110> FirstName : 曙 <110> FirstName : Dawn
<110> MiddleInitial : <110> MiddleInitial :
<110> Suffix : <110> Suffix:
the
Application Project Application Project
------------------- -------------------
<120> Title : 一种原发性肝细胞性肝癌相关的klotho基因单核苷酸多态性其构建方法及其 <120> Title : A single nucleotide polymorphism of klotho gene associated with primary hepatocellular carcinoma, its construction method and its
应用 Application
<130> AppFileReference : <130> AppFileReference :
<140> CurrentAppNumber : <140> CurrentAppNumber :
<141> CurrentFilingDate : ____-__-__ <141> CurrentFilingDate : ____-__-__
the
Sequence sequence
-------- --------
<213> OrganismName : <213> OrganismName :
<400> PreSequenceString : <400> PreSequenceString :
cgcgcagcat gcccgccagc gccccgccgc gccgcccgcg gccgccgccg ccgtcgctgt 60 cgcgcagcat gcccgccagc gccccgccgc gccgcccgcg gccgccgccg ccgtcgctgt 60
cgctgctgct ggtgctgctg ggcctgggcg gccgccgcct gcgtgcggag ccgggcgacg 120 cgctgctgct ggtgctgctg ggcctgggcg gccgccgcct gcgtgcggag ccgggcgacg 120
gcgcgcagac ctgggcccgt ttctcgcggc ctcctgcccc cgaggccgcg ggcctcttcc 180 gcgcgcagac ctgggcccgt ttctcgcggc ctcctgcccc cgaggccgcg ggcctcttcc 180
agggcacctt ccccgacggc ttcctctggg ccgtgggcag cgccgcctac cagaccgagg 240 agggcacctt ccccgacggc ttcctctggg ccgtgggcag cgccgcctac cagaccgagg 240
gcggctggca gcagcacggc aagggtgcgt ccatctggga tacgttcacc caccaccccc 300 gcggctggca gcagcacggc aagggtgcgt ccatctggga tacgttcacc caccacccccc 300
tggcaccccc gggagactcc cggaacgcca gtctgccgtt gggcgccccg tcgccgctgc 360 tggcaccccc gggagactcc cggaacgcca gtctgccgtt gggcgccccg tcgccgctgc 360
agcccgccac cggggacgta gccagcgaca gctacaacaa cgtcttccgc gacacggagg 420 agcccgccac cggggacgta gccagcgaca gctacaacaa cgtcttccgc gacacggagg 420
cgctgcgcga gctcggggtc actcactacc gcttctccat ctcgtgggcg cgagtgctcc 480 cgctgcgcga gctcggggtc actcactacc gcttctccat ctcgtgggcg cgagtgctcc 480
ccaatggcag cgcgggcgtc cccaaccgcg aggggctgcg ctactaccgg cgcctgctgg 540 ccaatggcag cgcgggcgtc cccaaccgcg aggggctgcg ctactaccgg cgcctgctgg 540
agcggctgcg ggagctgggc gtgcagcccg tggtcaccct gtaccactgg gacctgcccc 600 agcggctgcg ggagctgggc gtgcagcccg tggtcaccct gtaccactgg gacctgcccc 600
agcgcctgca ggacgcctac ggcggctggg ccaaccgcgc cctggccgac cacttcaggg 660 agcgcctgca ggacgcctac ggcggctggg ccaaccgcgc cctggccgac cacttcaggg 660
attacgcgga gctctgcttc cgccacttcg gcggtcaggt caagtactgg atcaccatcg 720 attacgcgga gctctgcttc cgccacttcg gcggtcaggt caagtactgg atcaccatcg 720
acaaccccta cgtggtggcc tggcacggct acgccaccgg gcgcctggcc cccggcatcc 780 acaaccccta cgtggtggcc tggcacggct acgccaccgg gcgcctggcc cccggcatcc 780
ggggcagccc gcggctcggg tacctggtgg cgcacaacct cctcctggct catgccaaag 840 ggggcagccc gcggctcggg tacctggtgg cgcacaacct cctcctggct catgccaaag 840
tctggcatct ctacaatact tctttccgtc ccactcaggg aggtcaggtg tccattgccc 900 tctggcatct ctacaatact tctttccgtc ccactcaggg aggtcaggtg tccattgccc 900
taagctctca ctggatcaat cctcgaagaa tgaccgacca cagcatcaaa gaatgtcaaa 960 taagctctca ctggatcaat cctcgaagaa tgaccgacca cagcatcaaa gaatgtcaaa 960
aatctctgga ctttgtacta ggttggtttg ccaaacccgt atttattgat ggtgactatc 1020 aatctctgga ctttgtacta ggttggtttg ccaaacccgt atttattgat ggtgactatc 1020
ccgagagcat gaagaataac ctttcatcta ttctgcctga ttttactgaa tctgagaaaa 1080 ccgagagcat gaagaataac ctttcatcta ttctgcctga ttttactgaa tctgagaaaa 1080
agttcatcaa aggaactgct gacttttttg ctctttgctt tggacccacc ttgagttttc 1140 agttcatcaa aggaactgct gacttttttg ctctttgctt tggacccacc ttgagttttc 1140
aacttttgga ccctcacatg aagttccgcc aattggaatc tcccaacctg aggcaactgc 1200 aacttttgga ccctcacatg aagttccgcc aattggaatc tcccaacctg aggcaactgc 1200
tttcctggat tgaccttgaa tttaaccatc ctcaaatatt tattgtggaa aatggctggt 1260 tttcctggat tgaccttgaa tttaaccatc ctcaaatatt tattgtggaa aatggctggt 1260
ttgtctcagg gaccaccaag agagatgatg ccaaatatat gtattacctc aaaaagttca 1320 ttgtctcagg gaccaccaag agagatgatg ccaaatatat gtattacctc aaaaagttca 1320
tcatggaaac cttaaaagcc atcaagctgg atggggtgga tgtcatcggg tataccgcat 1380 tcatggaaac cttaaaagcc atcaagctgg atggggtgga tgtcatcggg tataccgcat 1380
ggtccctcat ggatggtttc gagtggcaca gaggttacag catcaggcgt ggactcttct 1440 ggtccctcat ggatggtttc gagtggcaca gaggttacag catcaggcgt ggactcttct 1440
atgttgactt tctaagccag gacaagatgt tgttgccaaa gtcttcagcc ttgttctacc 1500 atgttgactt tctaagccag gacaagatgt tgttgccaaa gtcttcagcc ttgttctacc 1500
aaaagctgat agagaaaaat ggcttccctc ctttacctga aaatcagccc ctagaaggga 1560 aaaagctgat agagaaaaat ggcttccctc ctttacctga aaatcagccc ctagaaggga 1560
catttccctg tgactttgct tggggagttg ttgacaacta cattcaagta gataccactc 1620 catttccctg tgactttgct tggggagttg ttgacaacta cattcaagta gataccactc 1620
tgtctcagtt taccgacctg aatgtttacc tgtgggatgt ccaccacagt aaaaggctta 1680 tgtctcagtt taccgacctg aatgtttacc tgtgggatgt ccaccacagt aaaaggctta 1680
ttaaagtgga tggggttgtg accaagaaga ggaaatccta ctgtgttgac tttgctgcca 1740 ttaaagtgga tggggttgtg accaagaaga ggaaatccta ctgtgttgac tttgctgcca 1740
tccagcccca gatcgcttta ctccaggaaa tgcacgttac acattttcgc ttctccctgg 1800 tccagcccca gatcgcttta ctccaggaaa tgcacgttac attttcgc ttctccctgg 1800
actgggccct gattctccct ctgggtaacc agtcccaggt gaaccacacc atcctgcagt 1860 actgggccct gattctccct ctgggtaacc agtcccaggt gaaccacacc atcctgcagt 1860
actatcgctg catggccagc gagcttgtcc gtgtcaacat caccccagtg gtggccctgt 1920 actatcgctg catggccagc gagcttgtcc gtgtcaacat caccccagtg gtggccctgt 1920
ggcagcctat ggccccgaac caaggactgc cgcgcctcct ggccaggcag ggcgcctggg 1980 ggcagcctat ggccccgaac caaggactgc cgcgcctcct ggccaggcag ggcgcctggg 1980
agaaccccta cactgccctg gcctttgcag agtatgcccg actgtgcttt caagagctcg 2040 agaaccccta cactgccctg gcctttgcag agtatgcccg actgtgcttt caagagctcg 2040
gccatcacgt caagctttgg ataacgatga atgagccgta tacaaggaat atgacataca 2100 gccatcacgt caagctttgg ataacgatga atgagccgta tacaaggaat atgacataca 2100
gtgctggcca caaccttctg aaggcccatg ccctggcttg gcatgtgtac aatgaaaagt 2160 gtgctggcca caaccttctg aaggcccatg ccctggcttg gcatgtgtac aatgaaaagt 2160
ttaggcatgc tcagaatggg aaaatatcca tagccttgca ggctgattgg atagaacctg 2220 ttaggcatgc tcagaatggg aaaatatcca tagccttgca ggctgattgg atagaacctg 2220
cctgcccttt ctcccaaaag gacaaagagg tggctgagag agttttggaa tttgacattg 2280 cctgcccttt ctcccaaaag gacaaagagg tggctgagag agttttggaa tttgacattg 2280
gctggctggc tgagcccatt ttcggctctg gagattatcc atgggtgatg agggactggc 2340 gctggctggc tgagcccatt ttcggctctg gagattatcc atgggtgatg agggactggc 2340
tgaaccaaag aaacaatttt cttcttcctt atttcactga agatgaaaaa aagctaatcc 2400 tgaaccaaag aaacaatttt cttcttcctt atttcactga agatgaaaaa aagctaatcc 2400
agggtacctt tgactttttg gctttaagcc attataccac catccttgta gactcagaaa 2460 agggtacctt tgactttttg gctttaagcc attataccac catccttgta gactcagaaa 2460
aagaagatcc aataaaatac aatgattacc tagaagtgca agaaatgacc gacatcacgt 2520 aagaagatcc aataaaatac aatgattacc tagaagtgca agaaatgacc gacatcacgt 2520
ggctcaactc ccccagtcag gtggcggtag tgccctgggg gttgcgcaaa gtgctgaact 2580 ggctcaactc ccccagtcag gtggcggtag tgccctgggg gttgcgcaaa gtgctgaact 2580
ggctgaagtt caagtacgga gacctcccca tgtacataat atccaatgga atcgatgacg 2640 ggctgaagtt caagtacgga gacctcccca tgtacataat atccaatgga atcgatgacg 2640
ggctgcatgc tgaggacgac cagctgaggg tgtattatat gcagaattac ataaacgaag 2700 ggctgcatgc tgaggacgac cagctgaggg tgtattatat gcagaattac ataaacgaag 2700
ctctcaaagc ccacatactg gatggtatca atctttgcgg atactttgct tattcgttta 2760 ctctcaaagc ccacatactg gatggtatca atctttgcgg atactttgct tattcgttta 2760
acgaccgcac agctccgagg tttggcctct atcgttatgc tgcagatcag tttgagccca 2820 acgaccgcac agctccgagg tttggcctct atcgttatgc tgcagatcag tttgagccca 2820
aggcatccat gaaacattac aggaaaatta ttgacagcaa tggtttcccg ggcccagaaa 2880 aggcatccat gaaacattac aggaaaatta ttgacagcaa tggtttcccg ggcccagaaa 2880
ctctggaaag attttgtcca gaagaattca ccgtgtgtac tgagtgcagt ttttttcaca 2940 ctctggaaag attttgtcca gaagaattca ccgtgtgtac tgagtgcagt ttttttcaca 2940
cccgaaagtc tttactggct ttcatagctt ttctattttt tgcttctatt atttctctct 3000 cccgaaagtc tttactggct ttcatagctt ttctattttt tgcttctatt atttctctct 3000
cccttatatt ttactactcg aagaaaggca gaagaagtta caaatagttc tgaacatttt 3060 cccttatatt ttactactcg aagaaaggca gaagaagtta caaatagttc tgaacatttt 3060
tctattcatt cattttgaaa taattatgca gacacatcag ctgttaacca tttgcacctc 3120 tctattcatt cattttgaaa taattatgca gacacatcag ctgttaacca tttgcacctc 3120
taagtgttgt gaaactgtaa atttcataca tttgacttct agaaaacatt tttgtggctt 3180 taagtgttgt gaaactgtaa atttcataca tttgacttct agaaaacatt tttgtggctt 3180
atgacagagg ttttgaaatg ggcataggtg atcgtaaaat attgaataat gcgaatagtg 3240 atgacagagg ttttgaaatg ggcataggtg atcgtaaaat attgaataat gcgaatagtg 3240
cctgaatttg ttctcttttt gggtgattaa aaaactgaca ggcactataa tttctgtaac 3300 cctgaatttg ttctcttttt gggtgattaa aaaactgaca ggcactataa tttctgtaac 3300
acactaacaa aagcatgaaa aataggaacc acaccaatgc aacatttgtg cagaaatttg 3360 aacactaacaa aagcatgaaa aataggaacc acaccaatgc aacatttgtg cagaaatttg 3360
aatgacaaga ttaggaatat tttcttctgc acccacttct aaatttaatg tttttctgga 3420 aatgacaaga ttaggaatat tttcttctgc accacttct aaatttaatg tttttctgga 3420
agtagtaatt gcaagagttc gaatagaaag ttatgtacca agtaaccatt tctcagctgc 3480 agtagtaatt gcaagagttc gaatagaaag ttatgtacca agtaaccatt tctcagctgc 3480
cataataatg cctagtggct tcccctctgt caaatctagt ttcctatgga aaagaagatg 3540 cataataatg cctagtggct tcccctctgt caaatctagt ttcctatgga aaagaagatg 3540
gcagatacag gagagacgac agagggtcct aggctggaat gttcctttcg aaagcaatgc 3600 gcagatacag gagagacgac agaggtcct aggctggaat gttcctttcg aaagcaatgc 3600
ttctatcaaa tactagtatt aatttatgta tctggttaat gacatacttg gagagcaaat 3660 ttctatcaaa tactagtatt aatttatgta tctggttaat gacatacttg gagagcaaat 3660
tatggaaatg tgtattttat atgatttttg aggtcctgtc taaaccctgt gtccctgagg 3720 tatggaaatg tgtattttat atgatttttg aggtcctgtc taaaccctgt gtccctgagg 3720
gatctgtctc actggcatct tgttgagggc cttgcacata ggaaactttt gataagtatc 3780 gatctgtctc actggcatct tgttgagggc cttgcacata ggaaactttt gataagtatc 3780
tgcggaaaaa caaacatgaa tcctgtgata ttgggctctt caggaagcat aaagcaattg 3840 tgcggaaaaa caaacatgaa tcctgtgata ttgggctctt caggaagcat aaagcaattg 3840
tgaaatacag tataccgcag tggctctagg tggaggaaag gaggaaaaag tgcttattat 3900 tgaaatacag tataccgcag tggctctagg tggaggaaag gaggaaaaag tgcttattat 3900
gtgcaacatt atgattaatc tgattataca ccatttttga gcagatcttg gaatgaatga 3960 gtgcaacatt atgattaatc tgattataca ccatttttga gcagatcttg gaatgaatga 3960
catgaccttt ccctagagaa taaggatgaa ataatcactc attctatgaa cagtgacact 4020 catgaccttt ccctagagaa taaggatgaa ataatcactc attctatgaa cagtgacact 4020
actttctatt ctttagctgt actgtaattt ctttgagttg atagttttac aaattcttaa 4080 actttctatt ctttagctgt actgtaattt ctttgagttg atagttttac aaattcttaa 4080
taggttcaaa agcaatctgg tctgaataac actggatttg tttctgtgat ctctgaggtc 4140 taggttcaaa agcaatctgg tctgaataac actggatttg tttctgtgat ctctgaggtc 4140
tattttatgt ttttgctgct acttctgtgg aagtagcttt gaactagttt tactttgaac 4200 tattttatgt ttttgctgct acttctgtgg aagtagcttt gaactagttt tactttgaac 4200
tttcacgctg aaacatgcta gtgatatcta gaaagggcta attaggtctc atcctttaat 4260 tttcacgctg aaacatgcta gtgatatcta gaaagggcta attaggtctc atcctttaat 4260
gccccttaaa taagtcttgc tgattttcag acagggaagt ctctctatta cactggagct 4320 gccccttaaa taagtcttgc tgattttcag acagggaagt ctctctatta cactggagct 4320
gttttataga taagtcaata ttgtatcagg caagataaac caatgtcata acaggcattg 4380 gttttataga taagtcaata ttgtatcagg caagataaac caatgtcata acaggcattg 4380
ccaacctcac tgacacaggg tcatagtgta taataatata ctgtactata taatatatca 4440 ccaacctcac tgacacagggg tcatagtgta taataatata ctgtactata taatatatca 4440
tctttagagg tatgattttt tcatgaaaga taagcttttg gtaatattca ttttaaagtg 4500 tctttagagg tatgattttt tcatgaaaga taagcttttg gtaatattca ttttaaagtg 4500
gacttattaa aattggatgc tagagaatca agtttatttt atgtatatat ttttctgatt 4560 gacttattaa aattggatgc tagagaatca agtttatttt atgtatatat ttttctgatt 4560
ataagagtaa tatatgttca ttgtaaaaat ttttaaaaca cagaaactat atgcaaagaa 4620 ataagagtaa tatatgttca ttgtaaaaat ttttaaaaca cagaaactat atgcaaagaa 4620
aaaataaaaa ttatctataa tctcagaacc cagaaatagc cactattaac atttcctacg 4680 aaaataaaaa ttatctataa tctcagaacc cagaaatagc cactattaac atttcctacg 4680
tattttattt tacatagatc atattgtata tagttagtat ctttattaat ttttattatg 4740 tattttattt tacatagatc atattgtata tagttagtat ctttattaat ttttattatg 4740
aaactttcct ttgtcattat tagtcttcaa aagcatgatt tttaatagtt gttgagtatt 4800 aaactttcct ttgtcattat tagtcttcaa aagcatgatt tttaatagtt gttgagtatt 4800
ccaccacagg aatgtatcac aacttaaccg ttcccgtttg ttagactagt ttcttattaa 4860 ccaccacagg aatgtatcac aacttaaccg ttcccgtttg ttagactagt ttcttattaa 4860
tgttgatgaa tgttgtttaa aaataatttt gttgctacat ttactttaat ttccttgact 4920 tgttgatgaa tgttgtttaa aaataatttt gttgctacat ttactttaat ttccttgact 4920
gtaaagagaa gtaattttgc tccttgataa agtattatat taataataaa tctgcctgca 4980 gtaaagagaa gtaattttgc tccttgataa agtattatat taataataaa tctgcctgca 4980
actttttgcc ttctttcata atcataaaaa aa 5012 actttttgcc ttctttcata atcataaaaa aa 5012
<212> Type : DNA <212> Type : DNA
<211> Length : 5012 <211> Length : 5012
SequenceName : 1 SequenceName : 1
SequenceDescription : SequenceDescription :
the
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102997487A CN102796820B (en) | 2012-08-22 | 2012-08-22 | Hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102997487A CN102796820B (en) | 2012-08-22 | 2012-08-22 | Hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102796820A CN102796820A (en) | 2012-11-28 |
| CN102796820B true CN102796820B (en) | 2013-12-04 |
Family
ID=47196117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102997487A Expired - Fee Related CN102796820B (en) | 2012-08-22 | 2012-08-22 | Hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102796820B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961739A (en) * | 2012-12-12 | 2013-03-13 | 黄曙 | Application of KLOTHO protein |
| CN107312829A (en) * | 2017-04-24 | 2017-11-03 | 首都医科大学附属北京佑安医院 | The mononucleotide polymorphism site related from different recurrence possibility liver cancer and its application |
| CN107312830B (en) * | 2017-04-24 | 2021-04-13 | 首都医科大学附属北京佑安医院 | Single nucleotide polymorphism loci associated with liver cancer with different malignant degrees and its application |
| CN106957921B (en) * | 2017-05-18 | 2020-12-29 | 中国水产科学研究院珠江水产研究所 | SNP locus suitable for klotho gene of micropterus salmoides fed with artificial compound feed and application of SNP locus in breeding |
| CN107557461B (en) * | 2017-10-20 | 2021-02-19 | 武汉赛云博生物科技有限公司 | Detection method of nucleic acid mass spectrum for early screening of liver cancer susceptibility genes |
| CN108333355B (en) * | 2018-02-01 | 2020-05-26 | 黄曙 | Use of KLOTHO protein in preparation of reagent for diagnosing risk of gastrointestinal stromal tumor |
| CN112915192B (en) * | 2021-03-05 | 2022-10-25 | 南方医科大学南方医院 | Use of KP-1 in the preparation of drugs for the treatment of chronic liver disease |
| CN113444730A (en) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | Screening and constructing method of primary hepatocyte klotho gene transduction stem cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008135993A1 (en) * | 2007-05-08 | 2008-11-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Klotho protein and related compounds for the treatment and diagnosis of cancer |
| DK2269071T3 (en) * | 2008-03-19 | 2015-01-05 | China Synthetic Rubber Corp | METHOD AND REAGENTS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOM |
| CN101608217A (en) * | 2008-06-20 | 2009-12-23 | 上海主健生物工程有限公司 | Liver cancer genetic test kit |
| WO2010064247A1 (en) * | 2008-12-03 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for determining predisposition to cancer |
| EP2388336A1 (en) * | 2010-05-19 | 2011-11-23 | Signature Diagnostics AG | Method and kits for diagnosing colorectal cancer |
-
2012
- 2012-08-22 CN CN2012102997487A patent/CN102796820B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102796820A (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102796820B (en) | Hepatocellular carcinoma-related klotho gene single-nucleotide polymorphism and its construction method and use | |
| Akamatsu et al. | Common variants at 11q12, 10q26 and 3p11. 2 are associated with prostate cancer susceptibility in Japanese | |
| Kinnersley et al. | Genome-wide association study identifies multiple susceptibility loci for glioma | |
| Tian et al. | A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese | |
| Shih et al. | Association of TNF-α polymorphism with susceptibility to and severity of non-small cell lung cancer | |
| CN103981273B (en) | A group of mutation gene groups and detection kits for assessing breast cancer risk | |
| Zhong et al. | Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma | |
| Michiels et al. | Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers | |
| Xu et al. | Promoter polymorphisms in trefoil factor 2 and trefoil factor 3 genes and susceptibility to gastric cancer and atrophic gastritis among Chinese population | |
| Hu et al. | Mitochondrial DNA haplogroup confers genetic susceptibility to nasopharyngeal carcinoma in Chaoshanese from Guangdong, China | |
| Ge et al. | PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China | |
| Lin et al. | p53 codon 72 polymorphism as a progression index for bladder cancer | |
| Zhou et al. | Sequence variations of mitochondrial DNA D‑loop region in patients with acute myeloid leukemia | |
| Gandolfi et al. | The extent of whole‐genome copy number alterations predicts aggressive features in primary melanomas | |
| CN103502469B (en) | Ankylosing spondylitis susceptibility and mononucleotide polymorphism detection method, kit and use thereof | |
| Mohamed Yusoff et al. | Mitochondrial 10398A> G NADH-dehydrogenase subunit 3 of complex I is frequently altered in intra-axial brain tumors in Malaysia | |
| CN1987462A (en) | Probe for detecting matrilinear inheritance chondriosome deafness gene A1555G and its use | |
| CN107312837A (en) | A kind of primer sets of detection rs2066853 loci gene types and its detection kit and application | |
| CN108342488B (en) | Kit for detecting gastric cancer | |
| Shih et al. | Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer | |
| CN107312843B (en) | Application of KRBA1 gene mutation in preparation of breast cancer detection kit | |
| Hao et al. | ABCC9 is downregulated and prone to microsatellite instability on ABCC9tetra in canine breast cancer | |
| Gautam et al. | Genetic Association of Toll-Like Receptor 4 (TLR4) Gene Polymorphism (rs4986790) With Oral Squamous Cell Carcinoma (OSCC): A Pilot Case-Control Study | |
| Kawachi et al. | Deletion polymorphism at chromosome 3q26. 1 and oral squamous cell carcinoma | |
| CN106834468B (en) | AIM1 and EME1 susceptible SNP site detection reagent and kit for its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 Termination date: 20150822 |
|
| EXPY | Termination of patent right or utility model |

